$COAG

Wedbush Initiates Hemab Therapeutics at Outperform With $42 Price Target

Jefferies & Co Initiates Coverage on Hemab Therapeutics With Buy Rating, $39 Price Target

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target

Top Midday Gainers

Cue Biopharma (CUE) shares soared 144% a day after the company said it signed a roughly $30 million PIPE financing with certain investors, and also appointed Shao-Lee Lin as president and chief executive.More than 16.3 million shares of the company traded intraday compared with a daily average of about 356,000.Hemab Therapeutics (COAG) said Thursday it priced its initial public offering of 16.8 million shares at $18 per share for gross proceeds of $301.5 million.Shares, which began trading on the Nasdaq Global Select Market on Friday, were up 66% intraday, with a trading volume of 1.87 million.Twilio (TWLO) delivered Q1 results that exceeded expectations, with accelerating momentum across AI-driven use cases and stronger-than-expected business performance, Morgan Stanley said Friday in a report.Shares surged 20%, with intraday trading volume at over 4.44 million from a daily average of roughly 2.44 million.Price: $34.70, Change: $+19.96, Percent Change: +135.41%